NeuroOne Expands Executive Leadership with Promotion of Emily Johns to Chief Administrative Officer
NeuroOne Medical Technologies has promoted Emily Johns to Chief Administrative Officer, signaling strategic focus on operational infrastructure as the company scales its neurological disorder treatment technologies.
NeuroOne Medical Technologies Corporation has elevated Emily Johns to the expanded role of Chief Administrative Officer while she continues serving as General Counsel, a move that strengthens the company's leadership team during a period of strategic growth. The promotion reflects NeuroOne's commitment to building robust operational infrastructure as it scales its medical technology business focused on neurological disorders.
Johns, who joined NeuroOne earlier this year as General Counsel, will now oversee all human resources, compliance, security and risk management functions in addition to leading the company's legal strategy. Her expanded responsibilities come at a critical time for the medical technology firm as it works to commercialize its minimally invasive solutions for conditions including epilepsy, Parkinson's disease, and chronic pain.
Dave Rosa, President and CEO of NeuroOne, emphasized Johns' immediate impact since joining the organization. "In the short time that Emily has been with NeuroOne she has made impactful contributions to the organization and the future growth of the business," Rosa stated. "We look forward to her future contributions as we continue to scale our business."
The promotion signals NeuroOne's focus on strengthening its corporate governance and operational capabilities as it advances its medical technology portfolio. Johns brings substantial experience from her previous role as partner at Honigman LLP, where she represented numerous life sciences companies, including NeuroOne on transactional work since 2017. Her background also includes representing public companies in securities offerings and M&A transactions during her tenure at Sullivan & Cromwell LLP.
"I am honored to step into this role and continue building on the strong foundation our exceptional team has created," Johns commented. "As we look ahead, I look forward to strengthening our operations and infrastructure to help bring our life-changing technologies to more people."
NeuroOne's technology development focuses on improving surgical care options and outcomes for patients suffering from various neurological disorders. The company's solutions include EEG recording, stimulation and ablation technologies that may improve patient outcomes while reducing procedural costs. Additional information about the company's technology and development pipeline is available at https://www.nmtc1.com.
The leadership expansion occurs as NeuroOne continues developing its hi-definition solutions for neurological conditions while potentially pursuing applications in other medical areas such as depression, mood disorders, and artificial intelligence. Johns' combined legal and administrative expertise positions the company to navigate the complex regulatory landscape while scaling operations to support broader commercialization efforts.